Treatment Considerations for Patients With Metastatic Urothelial Carcinoma
Sumanta K. Pal, MD, associate professor of the Department of Medical Oncology and Experimental Therapeutics at City of Hope, discusses the data he considers when treating patients with metastatic urothelial carcinoma.
Sumanta K. Pal, MD, associate professor of the Department of Medical Oncology and Experimental Therapeutics at City of Hope, discusses the data he considers when treating patients with metastatic urothelial carcinoma.
While many agents have been approved for this disease, Pal says the decision will rely heavily on the physician’s comfort level with each of the agents when deciding which to use.
In Pal’s opinion, there is the highest amount of evidence with atezolizumab (Tecentriq) and pembrolizumab (Keytruda). When looking at data for atezolizumab from the IMvigor211 trial, many physicians found the results to be negative. However, one particular subset of patients in this study was given atezolizumab in comparison to agents like taxanes.
FDA Approves Nogapendekin Alfa Inbakicept for BCG-Unresponsive NMIBC Carcinoma In Situ
April 22nd 2024Patients with Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer carcinoma in situ now have a new treatment option following the FDA’s approval of nogapendekin alfa.
Read More
FDA Accepts IND for UGN-103 in Low-Grade Intermediate-Risk NMIBC
April 15th 2024An investigational new drug application for UGN-103 was accepted by the FDA. A phase 3 study to assess the safety and efficacy of the agent in low-grade intermediate-risk non-muscle invasive bladder cancer is anticipated.
Read More
